Journal
CANCER LETTERS
Volume 520, Issue -, Pages 68-79Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2021.07.002
Keywords
Cancer therapy; Cellular senescence; SASP; Senotherapy; Senolysis
Categories
Funding
- National Natural Science Foundation of China [81972300, 81502554]
- Natural Science Foundation Project of Chongqing [cstc2019jcyj-msxmX0669]
Ask authors/readers for more resources
Cellular senescence is a stress response that can have detrimental effects during cancer therapy, including promoting tumorigenesis and therapeutic resistance. Selective removal of senescent cells is considered a promising adjuvant approach to eliminate these adverse effects.
Cellular senescence is a stress response that imposes a growth arrest on cancer and nonmalignant cells during cancer therapy. By secreting a plethora of proinflammatory factors collectively termed the senescence-associated secretory phenotype (SASP), therapy-induced senescent cells can promote tumorigenesis. Moreover, the SASP from senescent cells is also able to drive therapy resistance and mediate many adverse effects of cancer therapy. Because senescent cell production often occurs during cancer therapy, it is important to carefully consider these potential detrimental effects. Senotherapy, which refers to selective removal of senescent cells, has been proposed as a promising adjuvant approach to eliminate the adverse effects of senescent cells. Thus, in this review we summarize in detail the mechanisms by which senescent cells contribute to tumorigenesis and therapeutic resistance. Also, we thoroughly discuss the potential strategies regarding how to effectively circumvent the undesirable effects of therapy-induced senescent cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available